Aimable Nahimana

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


49 publications

In press | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2006 | 2005 | 2004 | 2003 | 2001 | 2000 | 1998 |
In press
 
NAD+ Metabolism Restriction Boosts High-Dose Melphalan Efficacy in Patients with Multiple Myeloma.
Soncini D., Becherini P., Ladisa F., Ravera S., Chedere A., Gelli E., Giorgetti G., Martinuzzi C., Piacente F., Mastracci L. et al. Blood advances. Peer-reviewed.
[DOI][Pmid][serval:BIB_6A1D49B7E1D9]
2023
 
Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies
Giorgetti Giulia, Becherini Pamela, Maroto-Martin Elena, Fenoglio Daniela, Soncini Debora, Martinuzzi Claudia, Bruzzone Santina, Benzi Andrea, Nahimana Aimable, Uras Chiara Rosa Maria et al., 2023/11/02., 65th ASH Annual Meeting December 9-12, 2023 pp. 1951-1951 dans Blood.
[DOI][WoS][serval:BIB_28DB6B2A20C5]
 
The NAD + Metabolic Dependency Restriction Overcomes Drug-Resistance Phenotype of Multiple Myeloma CELLS
Soncini Debora, Becherini Pamela, Ravera Silvia, Martinuzzi Claudia, Nencioni Alessio, Bruzzone Santina, Piacente Francesco, Giorgetti Giulia, Ladisa Francesco, Duchosal Michel A. et al., 2023/11/02., 65th ASH Annual Meeting December 9-12, 2023 pp. 6609-6609 dans Blood.
[DOI][WoS][serval:BIB_072082D1398B]
Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.
Fratta S., Biniecka P., Moreno-Vargas A.J., Carmona A.T., Nahimana A., Duchosal M.A., Piacente F., Bruzzone S., Caffa I., Nencioni A. et al., 2023/03/15. European journal of medicinal chemistry, 250 p. 115170. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FD14B5315A4E]
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
Biniecka P., Matsumoto S., Belotti A., Joussot J., Bai J.F., Majjigapu S.R., Thoueille P., Spaggiari D., Desfontaine V., Piacente F. et al., 2023/02/16. Molecules, 28 (4) p. 1897. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9D877CB69A0A]
Nicotinaldehyde, a Novel Precursor of NAD Biosynthesis, Abrogates the Anti-Cancer Activity of an NAD-Lowering Agent in Leukemia.
Matsumoto S., Biniecka P., Bellotti A., Duchosal M.A., Nahimana A., 2023/01/27. Cancers, 15 (3) p. 787. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E7094DC4B76E]
2022
 
Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer.
Bai J.F., Majjigapu S.R., Sordat B., Poty S., Vogel P., Elías-Rodríguez P., Moreno-Vargas A.J., Carmona A.T., Caffa I., Ghanem M. et al., 2022/09/05. European journal of medicinal chemistry, 239 p. 114504. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0F68DEF85901]
Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.
Ghanem M.S., Caffa I., Del Rio A., Franco J., Parenti M.D., Monacelli F., Cea M., Khalifa A., Nahimana A., Duchosal M.A. et al., 2022/07/10. Pharmaceuticals, 15 (7) p. 848. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_844224CADBEE]
Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia.
ElMokh O., Matsumoto S., Biniecka P., Bellotti A., Schaeuble K., Piacente F., Gallart-Ayala H., Ivanisevic J., Stamenkovic I., Nencioni A. et al., 2022/04/08. Cell death & disease, 13 (4) p. 320. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D8A172BF5015]
2021
 
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition).
Klionsky D.J., Abdel-Aziz A.K., Abdelfatah S., Abdellatif M., Abdoli A., Abel S., Abeliovich H., Abildgaard M.H., Abudu Y.P., Acevedo-Arozena A. et al., 2021/01. Autophagy, 17 (1) pp. 1-382. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_345DDF9FE897]
2019
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent.
Cloux A.J., Aubry D., Heulot M., Widmann C., ElMokh O., Piacente F., Cea M., Nencioni A., Bellotti A., Bouzourène K. et al., 2019/11/19. Oncotarget, 10 (62) pp. 6723-6738. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_1BDC3B2158B7]
Experimental Drainage Device to Reduce Lymphoedema in a Rat Model.
Triacca V., Pisano M., Lessert C., Petit B., Bouzourene K., Nahimana A., Vozenin M.C., Stergiopulos N., Swartz M.A., Mazzolai L., 2019/06. European journal of vascular and endovascular surgery, 57 (6) pp. 859-867. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3C19755AAAE9]
The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance.
Vannini N., Campos V., Girotra M., Trachsel V., Rojas-Sutterlin S., Tratwal J., Ragusa S., Stefanidis E., Ryu D., Rainer P.Y. et al., 2019/03/07. Cell stem cell, 24 (3) pp. 405-418.e7. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9C9755E6E69D]
 
Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH.
Blanc Mettral J., Faller N., Cruchon S., Sottas L., Buclin T., Schild L., Choong E., Nahimana A., Decosterd L.A., 2019. Drug metabolism letters, 13 (2) pp. 102-110. Peer-reviewed.
[DOI][Pmid][serval:BIB_6F47958A0A5D]
2018
Activation of Bone Marrow-Derived Cells Angiotensin (Ang) II Type 1 Receptor by Ang II Promotes Atherosclerotic Plaque Vulnerability.
Pellegrin M., Bouzourène K., Aubert J.F., Nahimana A., Duchosal M.A., Mazzolai L., 2018/09/04. International journal of molecular sciences, 19 (9) pp. E2621. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DF24A17CD520]
 
Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells.
Bello C., Bai J., Zambron B.K., Elías-Rodríguez P., Gajate C., Robina I., Caffa I., Cea M., Montecucco F., Nencioni A. et al., 2018/04/25. European journal of medicinal chemistry, 150 pp. 457-478. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2B525FC316B2]
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.
Cagnetta A., Soncini D., Orecchioni S., Talarico G., Minetto P., Guolo F., Retali V., Colombo N., Carminati E., Clavio M. et al., 2018/01. Haematologica, 103 (1) pp. 80-90. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0A0458D4A8E8]
2017
 
Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Piacente F., Caffa I., Ravera S., Sociali G., Passalacqua M., Vellone V.G., Becherini P., Reverberi D., Monacelli F., Ballestrero A. et al., 2017/07/15. Cancer research, 77 (14) pp. 3857-3869. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D77736A5EF65]
2016
The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner.
Heulot M., Chevalier N., Puyal J., Margue C., Michel S., Kreis S., Kulms D., Barras D., Nahimana A., Widmann C., 2016/09/27. Oncotarget, 7 (39) pp. 64342-64359. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F2DA0AC290B8]
Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Sociali G., Raffaghello L., Magnone M., Zamporlini F., Emionite L., Sturla L., Bianchi G., Vigliarolo T., Nahimana A., Nencioni A. et al., 2016/01/19. Oncotarget, 7 (3) pp. 2968-2984. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_93788DFD2BBE]
2015
 
Combinative effects of β-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation.
Breton C.S., Aubry D., Ginet V., Puyal J., Heulot M., Widmann C., Duchosal M.A., Nahimana A., 2015. Biochimie, 116 pp. 141-153. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A4DEF65E413F]
2014
A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis.
Ginet V., Puyal J., Rummel C., Aubry D., Breton C., Cloux A.J., Majjigapu S.R., Sordat B., Vogel P., Bruzzone S. et al., 2014. Autophagy, 10 (4) pp. 603-617.
[URN][DOI][WoS][Pmid][serval:BIB_E0EC16EEBAEC]
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.
Breton C.S., Nahimana A., Aubry D., Macoin J., Moretti P., Bertschinger M., Hou S., Duchosal M.A., Back J., 2014. Journal of Hematology and Oncology, 7 p. 33. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_01E6AE78E68F]
 
The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody.
Nahimana A., Aubry D., Breton C.S., Majjigapu S.R., Sordat B., Vogel P., Duchosal M.A., 2014. Leukemia and Lymphoma, 55 (9) pp. 2141-2150.
[DOI][WoS][Pmid][serval:BIB_8DB096080B48]
2013
 
Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience.
Montecucco F., Cea M., Bauer I., Soncini D., Caffa I., Lasigliè D., Nahimana A., Uccelli A., Bruzzone S., Nencioni A., 2013. Current Drug Targets, 14 (6) pp. 637-643. Peer-reviewed.
[WoS][Pmid][serval:BIB_2F6E83FE64FD]
 
Nicotinamide phosphoribosyltransferase as a target in inflammation- related disorders.
Montecucco F., Cea M., Cagnetta A., Damonte P., Nahimana A., Ballestrero A., Rio A.D., Bruzzone S., Nencioni A., 2013. Current Topics in Medicinal Chemistry, 13 (23) pp. 2930-2938. Peer-reviewed.
[WoS][Pmid][serval:BIB_B7EE2B58FC75]
 
Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia.
Rabodonirina M., Vaillant L., Taffé P., Nahimana A., Gillibert R.P., Vanhems P., Hauser P.M., 2013. Emerging Infectious Diseases, 19 (1) pp. 21-28. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CE80293E8EF4]
2012
 
Guidelines for the use and interpretation of assays for monitoring autophagy.
Klionsky D.J., Abdalla F.C., Abeliovich H., Abraham R.T., Acevedo-Arozena A., Adeli K., Agholme L., Agnello M., Agostinis P., Aguirre-Ghiso J.A. et al., 2012/04. Autophagy, 8 (4) pp. 445-544. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_56859EA53CC8]
2011
A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants
Nahimana A., Aubry D., Lagopoulos L., Greaney P., Attinger A., Demotz S., Dawson K.M., Schapira M., Tschopp J., Dupuis M. et al., 2011. Blood Cancer Journal, 1 (12) pp. e47.
[URN][DOI][WoS][serval:BIB_F400AD0C819E]
 
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols.
Bello C., Dal Bello G., Cea M., Nahimana A., Aubry D., Garuti A., Motta G., Moran E., Fruscione F., Pronzato P. et al., 2011. Bioorganic and Medicinal Chemistry, 19 (24) pp. 7720-7727.
[DOI][WoS][Pmid][serval:BIB_516406B5E329]
2010
 
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies.
Bello C., Cea M., Dal Bello G., Garuti A., Rocco I., Cirmena G., Moran E., Nahimana A., Duchosal M.A., Fruscione F. et al., 2010/05/01. Bioorganic & medicinal chemistry, 18 (9) pp. 3320-3334. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FE0F7F1D0119]
Interhuman transmission as a potential key parameter for geographical variation in the prevalence of Pneumocystis jirovecii dihydropteroate synthase mutations.
Hauser P.M., Nahimana A., Taffe P., Weber R., Francioli P., Bille J., Rabodonirina M., 2010. Clinical Infectious Diseases, 51 (4) pp. e28-e33.
[URN][DOI][WoS][Pmid][serval:BIB_681454FC36EC]
2009
 
NAD targeting efficiently kills hematologic cancer cells [Response]
Nahimana A., Aubry D., Butcher S., Duchosal M. A., 2009. Blood, 113 (23) pp. 6037-6038. Peer-reviewed.
[DOI][WoS][serval:BIB_A870C2501B89]
 
The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.
Nahimana A., Attinger A., Aubry D., Greaney P., Ireson C., Thougaard A.V., Tjørnelund J., Dawson K.M., Dupuis M., Duchosal M.A., 2009. Blood, 113 (14) pp. 3276-3286.
[DOI][WoS][Pmid][serval:BIB_160C5D8712FE]
2006
 
A Fas agonist induces high levels of apoptosis in haematological malignancies
Greaney P., Nahimana A., Lagopoulos L., Etter A. L., Aubry D., Attinger A., Beltraminelli N., Huni B., Bassi I., Sordat B. et al., 2006/04. Leukemia Research, 30 (4) pp. 415-426.
[DOI][WoS][Pmid][serval:BIB_16BBB6FA9741]
 
Geographical variation in the prevalence of Pneumocystis jirovecii dihydropteroate synthase mutations within Western Europe
Rabodonirina M., Nahimana A., Weber R., Francioli P., Bille J., Hauser P. M., 2006. Journal of Eukaryotic Microbiology, 53 Suppl 1 pp. S112-3.
[DOI][WoS][Pmid][serval:BIB_446D86F22395]
2005
Molecular evidence of Pneumocystis transmission in pediatric transplant unit.
Höcker B., Wendt C., Nahimana A., Tönshoff B., Hauser P.M., 2005/02. Emerging infectious diseases, 11 (2) pp. 330-332. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B23005632BDD]
2004
 
Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis
Nahimana A., Rabodonirina M., Bille J., Francioli P., Hauser P. M., 2004/11. Antimicrobial Agents and Chemotherapy, 48 (11) pp. 4301-5.
[DOI][WoS][Pmid][serval:BIB_E7242DB55CCA]
Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients.
Rabodonirina M., Vanhems P., Couray-Targe S., Gillibert R.P., Ganne C., Nizard N., Colin C., Fabry J., Touraine J.L., van Melle G. et al., 2004. Emerging infectious diseases, 10 (10) pp. 1766-73. Peer-reviewed.
[URN][Pmid][serval:BIB_E98098077C99]
2003
Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients
Nahimana A., Rabodonirina M., Zanetti G., Meneau I., Francioli P., Bille J., Hauser P. M., 2003/10. Journal of Infectious Diseases, 188 (7) pp. 1017-23.
[URN][DOI][WoS][Pmid][serval:BIB_79DA7A2E9F6F]
Sulfa resistance and dihydropteroate synthase mutants in recurrent Pneumocystis carinii pneumonia.
Nahimana A., Rabodonirina M., Helweg-Larsen J., Meneau I., Francioli P., Bille J., Hauser P.M., 2003/07. Emerging infectious diseases, 9 (7) pp. 864-867. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B5C359953C66]
 
Pneumocystis jirovecii dihydrofolate reductase polymorphisms associated with failure of prophylaxis
Nahimana A., Rabodonirina M., Francioli P., Bille J., Hauser P. M., 2003. Journal of Eukaryotic Microbiology, 50 Suppl pp. 656-7.
[DOI][WoS][Pmid][serval:BIB_25A9A5B7D5DB]
2001
 
Rapid PCR-single-strand conformation polymorphism method to differentiate and estimate relative abundance of Pneumocystis carinii special forms infecting rats
Nahimana A., Cushion M. T., Blanc D. S., Hauser P. M., 2001/12. Journal of Clinical Microbiology, 39 (12) pp. 4563-5. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_676A20EBBD4B]
Prophylaxis failure is associated with a specific Pneumocystis carinii genotype.
Hauser P.M., Sudre P., Nahimana A., Francioli P., Study Group, 2001/10. Clinical Infectious Diseases, 33 (7) pp. 1080-1082. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C663940A6537]
 
Genetic diversity of Pneumocystis carinii in HIV-positive and -negative patients as revealed by PCR-SSCP typing
Hauser P. M., Blanc D. S., Sudre P., Senggen Manoloff E., Nahimana A., Bille J., Weber R., Francioli P., 2001/03. AIDS, 15 (4) pp. 461-6. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DCE7F682C21A]
2000
 
Determination of the copy number of the nuclear rDNA and beta-tubulin genes of Pneumocystis carinii f. sp. hominis using PCR multicompetitors
Nahimana A., Francioli P., Blanc D. S., Bille J., Wakefield A. E., Hauser P. M., 2000/08. Journal of Eukaryotic Microbiology, 47 (4) pp. 368-72. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E54F8EBD3D9D]
 
Typing of Pneumocystis carinii f. sp. hominis by PCR-SSCP to indicate a high frequency of co-infections
Nahimana A., Blanc D. S., Francioli P., Bille J., Hauser P. M., 2000/08. Journal of Medical Microbiology, 49 (8) pp. 753-8. Peer-reviewed.
[WoS][Pmid][serval:BIB_309BA0372A2C]
 
Carriage of Pneumocystis carinii by immunosuppressed patients and molecular typing of the organisms
Hauser P. M., Blanc D. S., Bille J., Nahimana A., Francioli P., 2000/03. AIDS, 14 (4) pp. 461-3. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_028DB3FD90EF]
1998
 
Potential coinfections complicate typing of Pneumocystis carinii f. sp. hominis
Hauser P. M., Blanc D. S., Telenti A., Nahimana A., Bille J., Francioli P., 1998/10. Journal of Clinical Microbiology, 36 (10) p. 3111. Peer-reviewed.
[WoS][Pmid][serval:BIB_95C853408545]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University